Purpose: Cytokine-based products are gaining importance for cancer immunotherapy. L19-TNF is a clinical-stage antibody-cytokine fusion protein that selectively accumulates to tumors and displays potent anticancer activity in preclinical models. Here, we describe an innovative approach to transiently inhibit off-target toxicity of L19-TNF, while maintaining antitumor activity.
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Translational Relevance:
The development of new strategies to improve the therapeutic window of cytokine-based biopharmaceuticals is one of the main challenges in the field of immunotherapy. One avenue toward the escalation of the MTD of antibody-cytokine fusion proteins is represented by the transient inhibition of the cytokine payload activity. In this article, we show that the MTD of the clinical stage immunocytokine L19-TNF can be increased by transient and selective inhibition of RIPK1 in various murine models of cancer. Our results clearly show that small molecule inhibitors of RIPK1, key mediator of TNF-induced inflammation and tissue damage, are ideal pharmaceutical tools to limit acute toxicity of L19-TNF. The findings included in this article are of clinical relevance, as patients treated with L19-TNF may benefit from judicious combinations with RIPK1 inhibitors, with potential improvement in terms of efficacy and safety of the treatment.
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Introduction
The therapeutic benefit associated with PD-1 blockade in a growing number of cancer indications [1] [2] [3] has stimulated the search for alternative immunotherapy strategies, that may be complementary to the use of immune checkpoint inhibitors. Cytokines represent a group of small immunoregulatory proteins, some of which have been considered for cancer therapy applications [4] . Recombinant interleukin-2 has been shown to eradicate metastatic melanoma or renal cell carcinoma in a small proportion of patients, who are fit enough to tolerate the severe side-effects associated with cytokine treatment [5, 6] . Recombinant tumor necrosis factor (TNF) in combination with melphalan has gained marketing authorization in Europe for the treatment of unresectable soft tissue sarcoma, in which TNF is administered through isolated limb perfusion procedure [7] .
Recombinant cytokines may cause substantial toxicity at very low doses (sometimes less than 1 mg per patient), thus preventing escalation to therapeutically active regimens. For example, the maximal tolerated dose (MTD) of TNF for systemic administration procedures was found to be 300 µg/patient [8] . The fusion of cytokine payloads with recombinant antibodies, capable of selective localization to the tumor, may represent a strategy for the improvement of the therapeutic index of cytokine-based biopharmaceuticals [9] [10] [11] [12] . Potent and selective anticancer activity has been observed in mouse models of cancer (particularly for fusion proteins based on IL2, IL12 and TNF payloads) [13] [14] [15] .
Two fusion proteins of the L19 antibody (specific to the alternatively-spliced EDB domain of fibronectin, a pan-tumoral antigen whose expression in normal tissues is limited to female reproductive organs) are currently being investigated in Phase III clinical trials in Europe and in the United States. L19-IL2 has shown initial signs of activity against various tumor entities, including metastatic melanoma [16] [17] [18] . L19-TNF and other TNF-based fusion proteins were found to be potently active against soft-tissue sarcoma and the fully-human fusion protein is currently being studied in pivotal trials in this indication, in combination with doxorubicin (NCT03420014, Eudract no. 2016-003239-38).
The targeted delivery of TNF causes a rapid and selective hemorrhagic tumor necrosis in mouse models of cancer [19] [20] [21] and in patients [22] . TNF also boosts the activity of NK cells and of CD8+ T cells, which are required in order to eliminate the minimal residual disease and lead to protective immunity in mice [21, 23] . However, TNF-based pharmaceuticals may cause toxicity, especially at early time points after intravenous administration, when the concentration in blood is highest. The most common side effects include a drop in blood pressure, flu-like symptoms, nausea and vomiting.
These toxicities typically disappear when the blood concentration of the product falls below a critical threshold [24] [25] [26] . It would be desirable to develop strategies that preserve the therapeutic activity of targeted TNF pharmaceuticals, while decreasing systemic toxicity [9] .
L19-TNF and related products provide a therapeutic benefit which is mediated by the durable high local concentration, that can be reached within the tumor mass. We reasoned that, if we were able to transiently inhibit TNF activity in blood (following intravenous administration of the product), we should be able to minimize side effects and safely administer higher doses of the product. One way to achieve this goal may be represented by the administration of small molecule inhibitors of key components in the TNF signaling pathway, building up activity at the tumor site, while decreasing systemic toxicity. Receptor-interacting protein kinase 1 (RIPK1) inhibitors may be ideally suited for this purpose, since RIPK1 is a key mediator of TNF-induced inflammation and tissue degeneration [27, 28] .
In this article, we report our findings on the combination of L19-hTNF (the clinical-stage fusion protein) or L19-mTNF (an analogue featuring murine TNF as therapeutic payload) with GSK'963, a selective RIPK1 inhibitor [29] . Combination therapy studies were also performed with ibuprofen, a non-steroidal anti-inflammatory drug, commonly used for the premedication of cancer patients undergoing cytokine treatment. The sequential administration of GSK'963 and L19-TNF did not inhibit the preferential accumulation of the antibody-cytokine fusion in the neoplastic mass and the induction of hemorrhagic necrosis in the tumor. The combination treatment allowed to safely administer L19-TNF beyond the maximal tolerated dose, with retention of potent anticancer activity.
By contrast, co-administration of L19-TNF and ibuprofen did not reduce body weight loss and treatment-related toxicity. The findings of this paper may be clinically relevant and may be applicable to other cytokine biopharmaceuticals. Combination regimens with judiciously-chosen small molecule inhibitors may allow to increase the maximal tolerated dose, thanks to a transient inhibition of signaling events in blood and in normal organs. A long residence time of the cytokine moiety within the tumor mass is less likely to be affected by the inhibitor, as small molecules are often cleared within minutes or hours.
Material and Methods
Compounds GSK'963 (Aobious), GSK'2982772, Necrostatin-1 and Necrostatin-1s (Nec-1 and Nec-1s; Selleck Chemicals) were dissolve in 100% DMSO at 10 mg/ml and kept at -20°C for long-term storage.
Ibuprofen sodium (Sigma-Aldrich) was prepared at 5 mg/ml in deionized water and stored at 4°C for no longer than 1 week. 
Protein Production
Cell Lines
Chinese Hamster Ovary cells (CHO-S; Invitrogen) were cultured in suspension in PowerCHO-2CD medium (Lonza), supplemented with Ultraglutamine-1 (4 mM; Lonza) and antibioticantimycotic (1%; AA; Gibco).
Murine cells lines F9 (embryonal teratocarcinoma), WEHI-164 (fibrosarcoma) and CT-26 (colon carcinoma) were obtained from American Type Culture Collection. Cells were cultured in the corresponding medium supplemented with Fetal Bovine Serum (10%; FBS; Invitrogen) and AA (1%) following the supplier's protocol and kept in culture for no longer than 10 passages with a confluence lower than 90%.
In Vitro Cytotoxicity Assay
The direct killing activity of L19-mTNF was determined in vitro on the fibrosarcoma WEHI-164 cell line. Cells were seeded in 96-well plates (20'000 cells/well) in RPMI-164 medium (Gibco).
After 24 hours, new medium containing decreasing concentration of L19-hTNF (1:10 dilution steps) with actinomycin D (Sigma; 2 µg/mL) was added to the cells, in the presence or absence of RIPK1 inhibitors (GSK'963, GSK'2982772, Nec-1 and Nec-1s; 1 µM). The cell viability was measured after 24 hours by adding 20 µl of CellTiter 96® AQueous One Solution Reagent (Promega) directly to the wells. The number of living cells was determined by measuring the absorbance after 4 hours at 490 nm using Spark multimode microplate reader (Tecan).
Experiments were performed in triplicate and the results were expressed as the percentage of cell viability compared with controls (cells treated with actinomycin D only).
Animal Experiments
All the animal studies were conducted in accordance with Swiss animal welfare laws and regulations (license number ZH04/2018, granted by Veterinäramt des Kantons Zürich).
Tumor Implantation F9 cells were grown to 80% confluence and detached with Trypsin-EDTA 0.05% (Life Technologies). Cells were washed with Hank's Balanced Salt Solution (HBSS, pH 7.4) once, counted and re-suspended in HBSS to a final concentration of 6.7 × 10 7 cells ml -1 . Aliquots of 10 7 cells (150 µl of suspension) were injected subcutaneously (s.c.) in the right flank of female 129/Sv mice (6-7 weeks of age, Janvier).
WEHI-164 and CT26 cells were grown to 80% confluence and detached with Trypsin-EDTA 0.05% (Life Technologies). Cells were washed with Hank's Balanced Salt Solution (HBSS, pH 7.4) once, counted and re-suspended in HBSS to a final concentration of 1.7 × 10 7 cells ml -1 .
Aliquots of 2.5 × 10 6 cells (150 µl of a suspension) were injected s.c. in the right flank of female BALB/c mice (6-7 weeks of age, Janvier).
Tumor volume was determined with the following formula: (d) 2 × D × 0.52, where d and D are the short and long dimensions in millimeters, respectively, measured with a caliper. Animals were sacrificed when termination criteria foreseen by the license were reached.
Cytokine analyses in plasma
Tumor-free BALB/c mice were injected intravenously (i.v.) with PBS, L19-mTNF (250 µg/Kg) or with GSK'963 (2 mg/Kg) followed by L19-mTNF (250 µg/Kg; 30 min later). After 2 hours, mice were euthanized and immediately exsanguinated. Blood was collected and incubated for 20 min in Microtainer tubes containing lithium heparin (BD Microtainer Tube). Plasma was obtained by centrifugation for 15 min at 3'000 rpm using a refrigerated centrifuge and stored at -80°C prior to cytokine quantification. IL2, IL6, IL10, MCP-1, IFN-g, TNF and IL1β cytokine plasma levels were quantified using a multiplexed bead-based flow cytometric assay kit (Bio-Techne AG, Zug, Switzerland) following the described procedure [32] at the Cytolab facility (Regensdorf, Switzerland).
Quantitative Biodistribution Experiment
The in vivo targeting performance of L19-hTNF was evaluated in biodistribution studies as previously described [33] . Briefly, the immunocytokine was radio-iodinated with 125 
Statistics
Data were analyzed using Prism 7.0 (GraphPad Software, Inc.). Student t test was used to assess the differences of cell viability and of cytokine levels between different experimental groups. In therapy experiments, statistical significances were determined with a regular 2-way ANOVA test (with Bonferroni post-test; *, p≤0.05; **, p≤0.01; ***, p≤0.001; and ****, p≤0.0001).
Results
Production of L19-TNF fusion proteins and quality control
L19-hTNF and L19-mTNF were produced in CHO cells and purified to homogeneity [Figure 1 ].
Sequences of the fusion proteins are described in the Supplementary Information. The proteins, which form stable non-covalent homotrimers thanks to the TNF moiety, were pure in SDS-PAGE analysis and eluted as single peak in gel-filtration. Deconvolution of LC-MS profile allowed identification of the expected experimental masses for L19-mTNF and L19-hTNF, which were compatible with the predicted values in the absence of any protein glycosylation [ Figure 1D and 1E].
RIPK1 inhibitors reduce in vitro potency of L19-TNF
Small molecule inhibitors of RIPK1 [29, 34, 35] , a key kinase in the signaling cascade of TNF through its TNF receptor 1 (TNFR1) [Figure 2A ], were tested in vitro for their ability to reduce potency of L19-mTNF. Cytotoxicity assays were performed on the murine fibrosarcoma WEHI-164 cell line. All four tested inhibitors (GSK'963, GSK'2982772, Nec-1 and Nec-1s) potently reduced TNF-mediated biocidal activity in a dose-dependent manner [ Figure 2B ]. Inhibition of the biocidal TNF activity by RIPK1 small molecule inhibitors was confirmed also for L19-hTNF on the WEHI-164 cell line [ Supplementary Figure 1] . For further investigations, we chose GSK'963 as combination partner for L19-TNF, since this molecule was slightly more active than the other inhibitors and since extensive information (e.g., metabolic stability, pharmacokinetic properties, efficacy in vivo) was available for this molecule [29] .
GSK'963 does not inhibit the ability of L19-mTNF to induce pro-inflammatory cytokines production in vivo
To characterize the immunological response to intravenously injected L19-mTNF, we measured plasma levels for a panel of relevant cytokines in immunocompetent tumor-free mice. L19-mTNF (given at the recommended dose of 250 µg/Kg) potently induced high levels of pro-inflammatory cytokines (e.g., IL6, MCP-1 and TNF) already two hours after the injection, compared with the non-treated control group [ Figure 3A] . Pre-treatment with GSK'963 did not change the cytokine level profile, compared with the L19-mTNF monotherapy group. However, MCP-1 (monocyte chemoattractant protein 1) slightly decreased when animals were treated with combinatorial treatment of L19-mTNF and GSK'963 (p<0.01). Figure 5C and 5D] did not interfere with the therapeutic potential of the immunocytokine compared to monotherapy. In a parallel therapy experiment, we replaced pre-treatment with GSK'963 by administration of the general anti-inflammatory drug ibuprofen (5 mg/Kg), 30 min prior to L19-mTNF injection (375 µg/Kg). In this case, ibuprofen was not able to revert the severe body weight loss [ Figure 5E and 5F] induced by administration of a high dose of L19-mTNF.
Discussion
We have described the use of a potent small molecule inhibitor of RIPK1 named GSK'963 for the improvement of the therapeutic window of an antibody-TNF fusion protein (L19-TNF) in preclinical models of cancer. Combination with GSK'963 enabled dose escalation of the immunocytokine beyond its MTD, while the single-dose administration of an equivalent amount of L19-TNF (375 g/Kg) was found to be lethal. Inhibition of RIPK1 did not interfere with selective accumulation of L19-TNF into neoplastic lesions, where high local concentrations of TNF caused onset of tumor vascular shutdown and selective hemorrhagic necrosis. In contrast with these findings, pre-administration of ibuprofen at its recommended dose did not have a similar beneficial effect in reducing toxicities related to the administration of targeted-TNF.
TNF is a potent cytokine mediator of inflammation which is expressed by macrophages, NK cells, T cells, endothelial cells and fibroblasts [36, 37] . Trimeric TNF interacts with two different receptors, TNFR1 and TNFR2, causing activation of complex signaling pathways that overall account for TNF-induced cell death, inflammation and cell activation [38, 39] . Tissue degeneration and inflammation is mainly promoted by the interaction of TNF with TNFR1 and by subsequent recruitment and activation of the intra-cellular RIPK1 protein [40] [41] [42] .
The use of recombinant TNF has been previously proposed for cancer therapy, but significant toxicities and lack of efficacy prevented its clinical success for systemic application [43, 44] .
Hypotension, leukopenia, thrombocytopenia, fever, headache, nausea and hepatopathy represent the most common side effects detected in Phase II studies with recombinant TNF, while most serious toxicities include respiratory failure and coagulopathies [45] . Our group has previously demonstrated that the generation of antibody-TNF fusion proteins capable to selectively accumulate to tumors after systemic administration represents a valuable strategy to improve therapeutic window and efficacy of TNF [19] [20] [21] . L19-TNF is an antibody-fusion protein for the targeting of the alternatively-spliced EDB domain of fibronectin [46] , that shows potent antitumor activity in preclinical models of cancer [13] [14] [15] and is now investigated in clinical trials [18, 22, 47] .
The product entered Phase III clinical trials in combination with L19-IL2 as neo-adjuvant therapy prior to surgery of fully-resectable Stage IIIB,C melanoma (NCT02938299 and NCT03567889).
Moreover, the combination of L19-TNF plus doxorubicin is being compared to doxorubicin monotherapy in pivotal trials as first-line treatment of advanced soft-tissue sarcoma (EudraCT 2016-003239-38 and NCT03420014).
While therapeutic activity can be dramatically improved by the selective delivery of cytokines to tumors via antibodies [19] [20] [21] , toxicity profile is often similar to the one of unmodified cytokines.
The majority of side effects of immunocytokines are typically observed in correspondence with the peak serum concentration of the product [18, 47] . Transient symptoms including chills, fever, fatigue and pain are for example observed already few minutes after L19-TNF infusion in patients, with a peak around 1-2 hours after application and a total duration of few hours [47] .
Pharmacological inhibition of cytokine activity shortly after intravenous administration represents an opportunity to improve the therapeutic window. Small molecules (like GSK'963) are particularly attractive for this application, since their serum half-life matches the clearance rate of recombinant antibody products from circulation [48] and inhibition of the cytokine activity may be harmonized with and prevent the onset of systemic side-effects of immunocytokines [29, 35, 39] .
We have successfully demonstrated that the MTD of L19-TNF can be increased by transient and selective inhibition of RIPK1, a key mediator of TNF-induced inflammation and tissue damage.
Moreover, our results clearly show small molecule inhibitors of RIPK1 are more effective in limiting the early toxicity of L19-TNF, as compared to general anti-inflammatory drugs like ibuprofen. Our results may be of clinical relevance, as patients treated with L19-TNF may benefit from judicious combinations with RIPK1 inhibitors, with potential improvement in terms of efficacy and safety of the treatment. Indeed, pharmacological approaches similar to the ones described in this article for L19-TNF may be applicable to other TNF-based pharmaceuticals or to other cytokine-based products. In particular, toxicities related to the administration of IL12-or 
